Specific therapy to regulate inflammation in rheumatoid arthritis: Molecular aspects

Immunotherapy

Volumn 6, Issue 5, 2014, Pages 623-636

  García Hernández, Mariana H ^a,b   González Amaro, Roberto ^c   Portales Pérez, Diana Patricia ^a  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

Biological and synthetic agent; Chronic inflammation; Cytokine; Inflammatory response; Molecular aspect; Therapeutic target

Indexed keywords

ABATACEPT; ADALIMUMAB; CLENOLIXIMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPRATUZUMAB; ETANERCEPT; IDEC 151; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE 3; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; IL6 PROTEIN, HUMAN;

DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMORAL IMMUNE DEFICIENCY; INFLAMMATION; LIGAND BINDING; MOLECULAR BIOLOGY; NONHUMAN; PREMATURE MORTALITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIUM; T LYMPHOCYTE ACTIVATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; B LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE DEPLETION; PATHOLOGY; T LYMPHOCYTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES;

EID: 84902073850     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.26     Document Type: Review

References (80)

1. Pelletier M, Maggi L, Micheletti A et al. Evidence for a cross-Talk between human neutrophils and Th17 cells. Blood 115(2), 335-343
2. Thairu N, Kiriakidis S, Dawson P, Paleolog E. Angiogenesis as a therapeutic target in arthritis in 2011: Learning the lessons of the colorectal cancer experience. Angiogenesis 14(3), 223-234 (2011).
3. Lefevre S, Knedla A, Tennie C et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat. Med. (12), 1414-1420 (2009).
4. Aravena O, Pesce B, Soto L et al. Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-gamma-producing NK cell and regulatory T cell subsets. Immunobiology 216(12), 1256-1263 (2011).
5. Mcgovern Jl, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-Tumor necrosis factor antibody therapy. Arthritis Rheum. 64(10), 3129-3138 (2012).
6. Yue C, You X, Zhao L et al. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/ IL-6 secretion in rheumatoid arthritis patients. Rheumatol. Int. 30(12), 1553-1557 (2010).
7. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-αlpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J. Exp. Med. 204(1), 33-39 (2007).
8. Aerts Ne, De Knop Kj, Leysen J et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-Associated chemokine receptor expression. Rheumatology (Oxford) 49(12), 2264-2272 (2010).
9. Kanbe K, Chiba J, Nakamura A. Decrease of CD68 and MMP-3 expression in synovium by treatment of adalimumab for rheumatoid arthritis. Int. J. Rheum. Dis. 14(3), 261-266 (2011).
10. Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann. Rheum. Dis. 69(6), 1200-1207 (2010).
11. Ray K. Rheumatoid arthritis: Anti-TNF therapy for RA hinders function and survival of dendritic cells. Nat. Rev. Rheumatol. 6(7), 383 (2010).
12. Balanescu A, Radu E, Nat R et al. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients. Int. J. Clin. Pharmacol. Res. 25(1), 9-18 (2005).
13. Taylor PC, Williams RO, Maini RN. Anti-TNF alpha therapy in rheumatoid arthritis-current and future directions. Curr. Dir. Autoimmun. 2, 83-102 (2000).
14. Hjeltnes G, Hollan I, Forre O et al. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-αlpha-inhibitor. Clin. Exp. Rheumatol. 31(3), 415-421 (2013).
15. Herenius MM, Thurlings RM, Wijbrandts CA et al. Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab. Ann. Rheum. Dis. 70(6), 1160-1162 (2011).
16. Aerts NE, De Knop KJ, Leysen J et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-Associated chemokine receptor expression. Rheumatology (Oxford) 49(12), 2264-2272
17. Shen H, Xia L, Lu J, Xiao W. Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J. Investig. Med. 58(7), 905-908 (2010).
18. Huang J, Xie B, Li Q et al. Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis. Eur. J. Pharmacol. 698(1-3), 429-434 (2013).
19. Zhu P, Lu N, Shi Zg et al. CD147 overexpression on synoviocytes in rheumatoid arthritis enhances matrix metalloproteinase production and invasiveness of synoviocytes. Arthritis Res. Ther. 8(2), R44 (2006).
20. Chara L, Sanchez-Atrio A, Perez A et al. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis. Arthritis Res. Ther. 14(4), R175 (2012).
21. Salinas Gf, De Rycke L, Barendregt B et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann. Rheum. Dis. 72(6), 1037-1043 (2013).
22. Kobie JJ, Zheng B, Bryk P et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-Tumor necrosis factor. Arthritis Res. Ther. 13(6), R209 (2011).
23. Salemi S, Picchianti-Diamanti A, Germano V et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: Safety and immunogenicity. Clin. Immunol. 134(2), 113-120 (2010).
24. Herenius MM, Oliveira AS, Wijbrandts CA, Gerlag DM, Tak PP, Lebre MC. Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: A new mechanism by which anti-TNF might reduce inflammation. PLoS ONE 8(2), e57802 (2013).
25. Varani K, Massara A, Vincenzi F et al. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-Tumor necrosis factor alpha but not methotrexate. Arthritis Rheum. 60(10), 2880-2891 (2009).
26. Mok CC, Van Der Kleij D, Wolbink GJ. Drug levels, antidrug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases. Clin. Rheumatol. 32(10), 1429-1435 (2013).
27. Gonzalez-Ruiz D, Gohlke H. Targeting protein-protein interactions with small molecules: Challenges and perspectives for computational binding epitope detection and ligand finding. Curr. Med. Chem. 13(22), 2607-2625 (2006).
28. Magne D, Palmer G, Barton Jl et al. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res. Ther. 8(3), R80 (2006).
29. Pham TN, Rahman P, Richardson VJ. Divergent effects of infliximab and anakinra therapies on macrophage phenotype from patients with refractory rheumatoid arthritis. Int. J. Immunopathol. Pharmacol. 23(2), 491-501 (2010).
30. Ikonomidis I, Lekakis JP, Nikolaou M et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117(20), 2662-2669 (2008).
31. Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 41(9), 972-980 (2002).
32. Varoga D, Pufe T, Harder J et al. Human beta-defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. Arthritis Rheum. 52(6), 1736-1745 (2005).
33. Yu P, Zheng C, Chen J et al. Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist. Bioorg. Med. Chem. 15(16), 5396-5405 (2007).
34. Yu P, Holt Lj, Basran A, Jones K et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel. 21(5), 283-288 (2008).
35. Ronga L, Jamieson Ag, Beauregard K, Quiniou C, Chemtob S, Lubell WD. Insertion of multiple alpha-Amino gamma-lactam (Agl) residues into a peptide sequence by solid-phase synthesis on synphase lanterns. Biopolymers 94(2), 183-191 (2010).
36. Quiniou C, Sapieha P, Lahaie I et al. Development of a novel noncompetitive antagonist of IL-1 receptor. J. Immunol. 180(10), 6977-6987 (2008).
37. Liu Z, Wyffels L, Barber C et al. Characterization of 99mTclabeled cytokine ligands for inflammation imaging via TNF and IL-1 pathways. Nucl. Med. Biol. 39(7), 905-915 (2012).
38. Wu C, Ying H, Bose S et al. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 1(4), 339-347 (2009).
39. Bar-or A, Fawaz L, Fan B et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann. Neurol. 67(4), 452-461 (2010).
40. Van De Veerdonk Fl, Lauwerys B, Marijnissen RJ et al. The anti-CD20 antibody rituximab reduces the T helper 17 response. Arthritis Rheum. 63(6), 1507-1516 (2011).
41. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res. Ther. 8(3), R83 (2006).
42. Melet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T-cell depletion in patients with rheumatoid arthritis: Association with clinical response. Arthritis Rheum. 65(11), 2783-2790 (2013).
43. Keren Z, Braun-Moscovici Y, Markovits D et al. Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-Anti-IL-8 autoantibody network. Clin. Immunol. 133(1), 108-116 (2009).
44. Dunussi-Joannopoulos K, Hancock Ge, Kunz A et al. B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model. Blood 106(7), 2235-2243 (2005).
45. Carnahan J, Wang P, Kendall R et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin. Cancer Res. 9(10 Pt 2), 3982S-3990S (2003).
46. Stohl W, Merrill JT, Mckay JD et al. Efficacy and safety of belimumab in patients with rheumatoid arthritis: A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study. J. Rheumatol. 40(5), 579-589 (2013).
47. Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibodydependent cellular cytotoxicity. J. Rheumatol. 34(11), 2204-2210 (2007).
48. Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3(11), 1097-1101 (2002).
49. Fallarino F, Grohmann U, Hwang KW et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4(12), 1206-1212 (2003).
50. Fallarino F, Grohmann U, Vacca C et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9(10), 1069-1077 (2002).
51. Pieper J, Herrath J, Raghavan S, Muhammad K, Vollenhoven R, Malmstrom V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 14, 34 (2013).
52. Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J. Clin. Immunol. 31(4), 588-595 (2011).
53. Cutolo M, Soldano S, Montagna P et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res. Ther. 11(6), R176 (2009).
54. Marti L, Golmia R, Golmia AP et al. Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann. NY Acad. Sci. 1173, 334-342 (2009).
55. Bonelli M, Ferner E, Goschl L et al. Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis. Arthritis Rheum. 65(3), 599-607 (2013).
56. Remans PH, Wijbrandts CA, Sanders ME et al. CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells. Arthritis Rheum. 54(10), 3135-3143 (2006).
57. Hepburn TW, Totoritis MC, Davis CB. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis. Rheumatology (Oxford) 42(1), 54-61 (2003).
58. Huxley P, Sutton Dh, Debnam P et al. High-Affinity small molecule inhibitors of T cell costimulation: Compounds for immunotherapy. Chem. Biol. 11(12), 1651-1658 (2004).
59. Haanstra KG, Endell J, Estevao D, Kondova I, Jonker M. Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses in rhesus monkeys. Clin. Exp. Immunol. 158(1), 91-98 (2009).
60. Maeda K, Mehta H, Drevets DA, Coggeshall KM. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood 115(23), 4699-4706 (2010).
61. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebocontrolled trial. Arthritis Rheum. 50(6), 1761-1769 (2004).
62. Carbone G, Wilson A, Diehl Sa, Bunn J, Cooper Sm, Rincon M. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int. J. Biol. Sci. 9(3), 279-288 (2013).
63. Mihara M, Ohsugi Y, Kishimoto T. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody. Biofactors 35(1), 47-51 (2009).
64. Samson M, Audia S, Janikashvili N et al. Brief report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 64(8), 2499-2503 (2012).
65. Fujimoto M, Nakano M, Terabe F et al. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J. Immunol. 186(1), 32-40
66. Lal G, Yin N, Xu J et al. Distinct inflammatory signals have physiologically divergent effects on epigenetic regulation of foxp3 expression and treg function. Am. J. Transplant. 11(2), 203-214 (2011).
67. Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171(3), 237-242 (2013).
68. Schultz O, Oberhauser F, Saech J et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS ONE 5(12), e14328 (2010).
69. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: A population-based study. Arthritis Rheum. 52(3), 722-732 (2005).
70. Snir A, Kessel A, Haj T, Rosner I, Slobodin G, Toubi E. Anti-IL-6 receptor antibody (tocilizumab): A B cell targeting therapy. Clin. Exp. Rheumatol. 29(4), 697-700 (2011).
71. Avdeeva AS, Aleksandrova EN, Novikov AA, Cherkasova MV, Panasyuk EY, Nasonov EL. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis]. Ter. Arkh. 85(5), 24-29 (2013).
72. Jazayeri JA, Upadhyay A, Vernallis AB, Carroll GJ. Targeting the glycoprotein 130 receptor subunit to control pain and inflammation. J. Interferon Cytokine Res. 30(12), 865-873 (2010).
73. Ghoreschi K, Jesson Mi, Li X et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186(7), 4234-4243 (2011).
74. Kubo S, Yamaoka K, Kondo M et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2013-203756 (2013) (Epub ahead of print).
75. Williams NK, Bamert RS, Patel O et al. Dissecting specificity in the Janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 387(1), 219-232 (2009).
76. Jiang JK, Ghoreschi K, Deflorian F et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3- (methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-y l)-3- oxopropanenitrile (CP-690,550). J. Med. Chem. 51(24), 8012-8018 (2008).
77. Pattison MJ, Mackenzie KF, Arthur JS. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J. Immunol. 189(6), 2784-2792 (2012).
78. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 60(5), 1232-1241 (2009).
79. Guma M, Hammaker D, Topolewski K et al. Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: Advantages of targeting upstream kinases MKK-3 or MKK-6. Arthritis Rheum. 64(9), 2887-2895 (2012).
80. Trujillo JI. MEK inhibitors: Apatent review 2008-2010. Expert Opin. Ther. Pat. 21(7), 1045-1069 (2011).